REGENXBIO Inc —— 资产负债表 (NASDAQ:RGNX) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 708.16 M1.11 B833.27 M573.97 M465.99 M453.03 M 负债总额 330.41 M349.61 M317.07 M262.23 M206.34 M350.3 M 权益总额 377.75 M764.3 M516.2 M311.74 M259.65 M102.73 M 负债及股东权益总额 708.16 M1.11 B833.27 M573.97 M465.99 M453.03 M 总债务 —————— 净债务 ——————

新闻

Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval

OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development

Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data

OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch

Regenxbio首席医疗官Pakola Steve出售5.3万美元RGNX股票

Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock

REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow (NASDAQ:RGNX) 2026-03-12

Stifel重申Regenxbio评级,基于杜氏肌营养不良症试验数据

Stifel reiterates Regenxbio stock rating on Duchenne trial data

Regenxbio公布杜氏肌营养不良基因疗法积极中期数据

Regenxbio reports positive interim data for Duchenne gene therapy

Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals - Regenxbio (NASDAQ:RGNX)